Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
0.8900
+0.0890 (11.11%)
Jun 29, 2026, 11:51 AM EDT - Market open
Dyadic International Revenue
Dyadic International had revenue of $1.11M in the quarter ending March 31, 2026, with 182.28% growth. This brings the company's revenue in the last twelve months to $3.81M, up 7.13% year-over-year. In the year 2025, Dyadic International had annual revenue of $3.09M, down -11.59%.
Revenue (ttm)
$3.81M
Revenue Growth
+7.13%
P/S Ratio
8.33
Revenue / Employee
$761,546
Employees
5
Market Cap
32.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.09M | -405.04K | -11.59% |
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.49K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | 1.68M | 385.63K | 29.77% |
| Dec 31, 2018 | 1.30M | 537.03K | 70.81% |
| Dec 31, 2017 | 758.42K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Kyntra Bio | 7.44M |
| Plus Therapeutics | 5.18M |
| Vistagen Therapeutics | 1.27M |
| Daré Bioscience | 1.16M |
| Lisata Therapeutics | 170.00K |
| Actinium Pharmaceuticals | 90.00K |
DYAI News
- 4 hours ago - Dyadic International allowed claims by Japan Patent Office - TheFly
- 4 hours ago - Dyadic Expands IP Protection and Business Development Activities in Japan - GlobeNewsWire
- 7 days ago - An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets - Newsfile Corp
- 11 days ago - Dyadic International Transcript: AGM 2026 - Transcripts
- 11 days ago - Dyadic International Proxy statement: Proxy filing - Filings
- 14 days ago - Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption - GlobeNewsWire
- 4 weeks ago - Dyadic International Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 4 weeks ago - Dyadic International, Scripps Research team to evaluate Hantavirus vaccine - TheFly